Browsing Tag
Multiple sclerosis
15 posts
How real-world evidence and pediatric studies may determine BRIUMVI’s ceiling in relapsing multiple sclerosis
Find out how real-world data and pediatric studies could define the long-term ceiling for TG Therapeutics’ BRIUMVI in relapsing multiple sclerosis.
Tiziana Life Sciences strengthens intranasal foralumab development with Renaissance Lakewood partnership
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a clinical-stage biotechnology company focused on immunomodulation therapies, has announced a strategic…
Teva Pharmaceuticals slammed with €462.6m fine for blocking Copaxone competitors
Teva Pharmaceuticals, the generics powerhouse, has been slapped with a hefty fine of €462.6 million by the European…
Merz Therapeutics acquires INBRIJA and FAMPYRA from Acorda Therapeutics to bolster neurological portfolio
In a strategic move enhancing its presence in the neurology sector, Merz Therapeutics has successfully completed the acquisition…
Nura Bio kicks off Phase 1 clinical trials for SARM1 inhibitor NB-4746
Nura Bio, a leading biopharmaceutical company specializing in neuroprotective, small molecule therapies, announced today the initiation of Phase…
Glenmark Pharmaceuticals introduces Fingolimod Capsules in US
India-based Glenmark Pharmaceuticals said that its subsidiary Glenmark Pharmaceuticals Inc., USA has introduced its Fingolimod Capsules, 0.5 mg…
Digital medicine firm Akili Interactive to merge with Social Capital Suvretta
Akili Interactive, a US-based digital medicine company, has agreed to merge with Social Capital Suvretta Holdings Corp. I…
Novartis bags Kesimpta FDA approval for relapsing forms of MS
Kesimpta FDA approval for RMS: Novartis has bagged approval from the US Food and Drug Administration (FDA) for…
Mylan gets favorable court decision in Biogen’s Tecfidera patent case
Dutch generic drugmaker Mylan said that the US District Court for the Northern District of West Virginia has…
Janssen’s Ponesimod OPTIMUM trial in MS meets primary endpoint
Ponesimod OPTIMUM trial results : Johnson & Johnson’s Janssen Pharmaceutical said that the phase 3 OPTIMUM clinical trial…